AstraZeneca Sponsored Symposium

Annual Meeting of the CAP-ACP Focusing the Canadian lens: Addressing the complexity of

EGFR-T790M in NSCLC and PD-L1 biomarker testing

Room: MacDonald Ballroom, Delta Prince Edward , Charlottetown, PEI

Sunday 11 June 2017 • 12:00 – 13:30

Chair: Alan Spatz, Director of Pathology,Jewish General Hospital, Montreal

LEARNING OBJECTIVES

• Understand the clinical value of EGFR-T790M and PD-L1 testing and the future impact on patient management

• Highlight the approaches to address the future challenges and opportunities for EGFR-T790M and PD-L1 testing

The AstraZeneca logo is a registered trade-mark of AstraZeneca AB.

Lunch will be provided. Please RSVP to info@cap-acp.org

and PD-L1 testing

AGENDA

New paradigms in the molecular pathology of NSCLC and the impact on clinical value for patients

Mahmoud Abdelsalam, Head and Chair of Hematology / Oncology Division, Director of Oncology Clinical Trial, The Moncton Hospital, Moncton

Future approaches to address the complexity of EGFR-T790M testing for patients with advanced NSCLCAlan Spatz, Director of Pathology, Jewish General Hospital, Montreal

PD-L1 testing in NSCLC and beyond: A comparison of PD-L1 assaysMichelle Downes, Director of Research, Department of Anatomic Pathology, Sunnybrook

Health Sciences Centre, Toronto

Panel discussion and Q&A: Evolution of EGFR-T790M and PD-L1 testing; where do we go from here?

Faculty and Audience